0
Inquiry Basket

There is no product in the shopping cart, buy it!

Quantitative Human APP (Glycosylated) Sandwich ELISA Kit (CAT#: GLJF-0525-HX176)

Datasheet
SizeQtyAdd To Basket
1×48 T
1×96 T

Product Description The quantitative human APP (glycosylated) sandwich ELISA kit is designed to detect human amyloid precursor protein (APP) levels. APP is a transmembrane protein involved in neuronal growth, survival, and repair, and is a precursor to amyloid-β peptide, a key component of plaques in Alzheimer's disease. The kit is suitable for various biological samples such as serum, plasma. Its sensitivity is 32.752 pg/mL, which can accurately detect low concentrations of APP in the sample.
Target APP
N-Glycosylation Site 542, 571
O-Glycosylation Site 633, 651, 652, 656, 659, 663, 667, 681
Sample Types Serum, plasma
Sample Volume 100 μL
Sensitivity 32.752 pg/mL
Detection Principle Quantitative sandwich ELISA
Detection Range 100 pg/mL-4000 pg/mL
Detection Time 1 h-5 h
Detection Wavelength 450 nm
Storage Store at 2-8°C for long term storage.
Species Human
Full Name Amyloid precursor protein
Alternate Names APP; Amyloid precursor protein; ABPP; APPI; PN2; Peptidase nexin-II
Uniprot No. P05067
Application The quantitative human APP (glycosylated) sandwich ELISA kit is valuable in research investigating Alzheimer's disease, neuronal function, and APP-related disorders. Researchers utilize this ELISA to quantify APP levels, providing insights into its role in these conditions and potential diagnostic or therapeutic applications.
Kit Components Pre-coated ELISA plate; Lyophilized standard; Biotin-labeled antibody; HRP-avidin; Various diluents; Wash buffer; TMB chromogenic substrate; Stop solution
Precision Intra-Assay: n=20, CV <8%;
Inter-Assay: n=20, CV <10%;
Recovery Serum sample: n=5, 80-105%;
Plasma sample: n=4, 90-105%;
Standard Curve
The standard curve is for reference only, and a new standard curve should be generated for each set of samples tested.
For Research Use Only.
Online Inquiry
Creative Biolabs-Glycoprotein Follow us on